Check Claims Before You Publish

Author Review: Andreas Villunger — Visual, Evidence‑First

Visualizations first: citation impact of representative high‑visibility papers where Villunger is an author. Below: direct paper citation counts (OpenAlex extracted top works that list Villunger among authors). Each datapoint is cited source‑paper (DOI linked in captions).

Data sources: OpenAlex top works listing for Andreas Villunger; DOIs for each paper linked below for traceability.

• LDHA lactic acid — Cell Metabolism 2016: LDHA/Immunosuppression Cell Metab 2016
• p53/Puma/Noxa — Science 2003: Puma/Noxa Science 2003

Evidence synthesis (claims & supporting sources)

1. High-impact coauthorships: Villunger appears as author on multiple widely-cited works in apoptosis and cancer biology (Science 2001, Science 2003, Cell Metabolism 2016), which indicates substantive contributions to key mechanistic topics (BH3-only proteins, apoptosis regulation, tumour immunometabolism). Bmf Science 2001 Puma/Noxa Science 2003
2. Breadth vs profile ambiguity: metadata provided by different sources is inconsistent: a short local summary lists h-index 3, 40 citations, 17 papers (likely a specific profile snapshot), while OpenAlex returns a top author profile giving works_count ~297, cited_by_count ~23,785 and h_index ~67 — indicating either conflation of multiple persons with same name or multiple profile clusters. This ambiguity requires authoritative disambiguation (ORCID is present for one OpenAlex profile: https://orcid.org/0000-0001-8259-4153). [No DOI; evidence is OpenAlex metadata extracted in the input.]
3. Consistent research themes: Villunger's visible contributions cluster on apoptosis (BCL-2 family, BH3-only proteins), cell death nomenclature/standards (NCCD recommendations) and cancer cell biology — supported by multiple review and experimental articles. NCCD recommendations 2014
4. Recent methodological & translational reach: coauthorship on metabolic‑immunology (LDHA/Cell Metabolism) shows interdisciplinary reach beyond classical apoptosis to tumor immunometabolism, increasing translational relevance. LDHA/Immunosuppression Cell Metab 2016
5. Reproducibility & reporting issues flagged: one correction in the literature (TNF dose misreporting corrected 2018) shows attention to methods accuracy but also underscores need for meticulous methods reporting. Bad TNF correction 2018

Critical strengths, blindspots, and recommendations (evidence‑weighted)

• Strengths: coauthorship on highly cited, methodologically diverse papers spanning mechanistic molecular biology to translational tumor metabolism; presence on top‑work lists with high citation counts supports influential contributions in apoptosis and cancer biology (Puma/Noxa Science 2003).
• Blindspots / risks: conflicting bibliometric snapshots (small-profile vs OpenAlex large-profile) risk mistaken identity; several high‑impact papers are collaborative with leading groups (Strasser, Adams, others), so attributing sole credit requires reading author contribution statements. A correction for method reporting suggests vigilance about exact methods metadata (Bad TNF correction 2018).
• Recommendations to the user / evaluator: (1) disambiguate the author identity via ORCID (https://orcid.org/0000-0001-8259-4153) and institutional profile to unify metrics; (2) inspect author contribution and funding statements in specific high‑impact papers before judging individual credit; (3) for reproducibility assessment, check corrections/supplementary methods and raw data deposition for each target paper.

What would change the assessment?

The current evaluation rests on (A) representative high‑impact coauthored papers and (B) conflicting bibliometric snapshots. Definitive reassessment would require authoritative disambiguation (ORCID-linked institutional CV or Scopus/Clarivate profile), access to author contribution statements for major papers, and raw data availability records. If those showed limited direct contribution to the high‑impact papers, the appraisal would lower; conversely, ORCID‑verified leadership roles on major papers would raise the assessment.

Selected citations (traceable evidence for claims above)

• Puma/Noxa Science 2003
• LDHA/Immunosuppression Cell Metab 2016
• Bmf Science 2001
• NCCD recommendations 2014
• Bad TNF correction 2018